Tapinarof Cream for Eczema: A Guide to the ADORING Trials
When eczema makes practice, school or sleep difficult, families may hear about a prescription called tapinarof. It is a nonsteroidal topical medicine, not a cosmetic cream. The question is whether its evidence and safety profile fit the person's care plan.
Who was studied?
The ADORING 1 and 2 randomized trials, published in 2024, enrolled 813 adults and children aged 2 and older with moderate-to-severe atopic dermatitis. They compared tapinarof 1% with its vehicle, an otherwise similar cream without the active medicine, for eight weeks. Most participants were children or adolescents.
| Eight-week outcome | Tapinarof | Vehicle |
|---|---|---|
| ADORING 1 | 45.4% | 13.9% |
| ADORING 2 | 46.4% | 18.0% |
These are the percentages achieving a clinician score of clear or almost clear skin plus at least a two-grade improvement. They are not the percentage cured. The trials did not compare tapinarof with Dr. Arsy #003; eight-week results cannot settle long-term safety.
Plan the conversation
The U.S. prescribing information describes use for atopic dermatitis in adults and children age 2 and older. Potential reactions include inflammation of hair follicles and application-site reactions. Ask the prescriber how to respond to a new rash and when to reassess. Bring the full list of topical products rather than guessing about application order around sports.
Compare the evidence with our guide to crisaborole trials, and see practical questions about storing medicine at a tournament.
For everyday dry-skin hydration, Dr. Arsy Moisturizer #003 is a cosmetic moisturizer for dry, sensitive and eczema-prone skin. It does not treat eczema or replace prescribed care. The studies discussed did not test #003.
NIAMS: Learn more about atopic dermatitis.
Educational information from the Dr. Arsy editorial team; discuss personal medical decisions with your clinician. Cited researchers and organizations do not endorse this product. Image is an AI-generated editorial illustration.